Search This Blog

Tuesday, March 10, 2026

Vertex's povetacicept meets primary and key secondary endpoints in Phase 3 IgA nephropathy trial

 


  • RAINIER 36-week interim analysis supports plan to complete rolling BLA submission by end of March for potential accelerated FDA approval.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)